This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: impaired glucose tolerance

March 2014 Br J Cardiol 2014;21:16

In brief

BJCardio Staff

Abstract

New drugs for diabetes A new DPP-4i for the management of type 2 diabetes, alogliptin (Vipidia®) has been launched by Takeda in the UK following data from EXAMINE, an outcome trial conducted in high risk acute coronary syndrome patients (see Br J Cardiol 2013;4:131) where the drug significantly reduced glucose levels and also demonstrated cardiovascular safety. Alogliptin and the fixed-dose combination product alogliptin and metformin (Vipdomet®) are now available in the UK. Alogliptin is licensed for the treatment of type 2 diabetes mellitus in adults aged 18 years and older to improve glycaemic control in combination with other glucose-lo

| Full text
Drugs for diabetes: part 4 acarbose

April 2011 Br J Cardiol 2011;18:78−81

Drugs for diabetes: part 4 acarbose

Ganesan Arungarinathan, Gerard A McKay, Miles Fisher

Abstract

(more…)

| Full text

March 2004 Br J Cardiol 2004;11:138-43

Will prevention of type 2 diabetes reduce the future burden of cardiovascular disease? The evidence base today

ohn HB Scarpello

Abstract

No content available

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now